Highlight
– In the 24-week RECAM phase III trial, chiglitazar 32 mg and 48 mg added to metformin reduced HbA1c by a least-squares mean of -0.91% and -1.14%, respectively, versus -0.49% with placebo (both active doses p < 0.001 versus placebo). 48 mg produced a greater reduction than 32 mg (p = 0.008).
– Chiglitazar also improved fasting and postprandial glucose and produced favorable lipid effects (lower triglycerides and free fatty acids, higher HDL-C).
– Safety profile was broadly comparable to placebo; the most notable treatment-related findings were modest weight gain and mild peripheral oedema in the chiglitazar arms.
